WHO approves emergency use of China’s Sinopharm vaccine | Daily News
COVID-19:

WHO approves emergency use of China’s Sinopharm vaccine

The World Health Organisation announced today it had approved a Covid-19 vaccine from China’s state-owned drugmaker Sinopharm for emergency use. The vaccine, one of two main Chinese coronavirus vaccines that collectively have already been given to hundreds of millions of people in China and elsewhere, is the first developed by a non-Western country to win WHO backing. It is also the first time the WHO has given emergency use approval to a Chinese vaccine for any infectious disease. A WHO emergency listing is a signal to national regulators that a product is safe and effective. It also allows it to be included in COVAX, a global programme to provide vaccines mainly for poor countries, which has hit supply problems. (Reuters)

 


Update:

WHO approves Sinopharm vaccine

The World Health Organization (WHO) on Friday approved China’s Sinopharm’s Covid-19 vaccine for Emergency Use, easing the way for poorer nations to get access to another much-needed shot to help end the pandemic. Sinopharm is the first Chinese shot to be classified as safe and effective by the W.H.O.

The approval allows the Sinopharm vaccine to be included in Covax, the World Health Organization’s global initiative that is designed to promote equitable vaccine distribution around the world.

Reliable vaccine access could improve further next week when the W.H.O. considers another Chinese shot, made by the company Sinovac.

Andrea Taylor, who analyzes global data on vaccines at the Duke Global Health Institute, called the potential addition of two Chinese vaccines into the Covax program a “game changer.”

“The situation right now is just so desperate for low- and lower-middle-income countries that any doses we can get out are worth mobilizing,” Ms. Taylor said.

“Having potentially two options coming from China could really change the landscape of what’s possible over the next few months.”

For China, the approval represents a high point in its vaccine diplomacy efforts and a chance to fill the gap left by Western nations and pharmaceutical companies in low- and middle-income countries. (NYT)